Role of antiphospholipid score and anti-β2-glycoprotein I Domain I autoantibodies in the diagnosis of antiphospholipid syndrome.

[1]  Ji-Eun Kim,et al.  Clinical performance of anticardiolipin and anti&bgr;2 glycoprotein I antibodies using a new automated chemiluminescent assay: superior thrombotic prediction of combined results measured by two different methods , 2014, Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis.

[2]  A. Hoxha,et al.  Confirmation of initial antiphospholipid antibody positivity depends on the antiphospholipid antibody profile , 2013, Journal of thrombosis and haemostasis : JTH.

[3]  M. Petri,et al.  Utility of Antiphosphatidylserine/Prothrombin and IgA Antiphospholipid Assays in Systemic Lupus Erythematosus , 2013, The Journal of Rheumatology.

[4]  M. Khamashta,et al.  Autoantibodies to domain 1 of beta 2 glycoprotein 1: a promising candidate biomarker for risk management in antiphospholipid syndrome. , 2012, Autoimmunity reviews.

[5]  K. Devreese,et al.  Performance of two new, automated chemiluminescence assay panels for anticardiolipin and anti‐beta2‐glycoprotein I antibodies in the laboratory diagnosis of the antiphospholipid syndrome , 2012, International journal of laboratory hematology.

[6]  D. Roccatello,et al.  Independent validation of the antiphospholipid score for the diagnosis of antiphospholipid syndrome , 2012, Annals of the rheumatic diseases.

[7]  M. Lockshin,et al.  APS ACTION – AntiPhospholipid Syndrome Alliance For Clinical Trials and InternatiOnal Networking , 2012, Lupus.

[8]  D. Noubouossie,et al.  AN AUTOMATED CHEMILUMINESCENCE IMMUNOASSAY MAY DETECT MOSTLY RELEVANT IgG ANTICARDIOLIPIN ANTIBODIES ACCORDING TO REVISED SYDNEY CRITERIA , 2012, Acta clinica Belgica.

[9]  L. Bianchi,et al.  Development and performance evaluation of novel chemiluminescence assays for detection of anti-PR3 and anti-MPO antibodies. , 2012, Clinica chimica acta; international journal of clinical chemistry.

[10]  A. Ruffatti,et al.  What Have We Learned about Antiphospholipid Syndrome from Patients and Antiphospholipid Carrier Cohorts? , 2012, Seminars in Thrombosis & Hemostasis.

[11]  Takao Koike,et al.  Efficacy of the antiphospholipid score for the diagnosis of antiphospholipid syndrome and its predictive value for thrombotic events. , 2012, Arthritis and rheumatism.

[12]  Kamil Fijorek,et al.  BDTcomparator: a program for comparing binary classifiers , 2011, Bioinform..

[13]  C. Maas,et al.  Immune responses against domain I of β(2)-glycoprotein I are driven by conformational changes: domain I of β(2)-glycoprotein I harbors a cryptic immunogenic epitope. , 2011, Arthritis and rheumatism.

[14]  Sabino Iliceto,et al.  Incidence of a first thromboembolic event in asymptomatic carriers of high-risk antiphospholipid antibody profile: a multicenter prospective study. , 2011, Blood.

[15]  A. Tincani,et al.  Risk factors for pregnancy failure in patients with anti-phospholipid syndrome treated with conventional therapies: a multicentre, case-control study. , 2011, Rheumatology.

[16]  P. Meroni,et al.  Pathogenesis of antiphospholipid syndrome: understanding the antibodies , 2011, Nature Reviews Rheumatology.

[17]  P. Groot,et al.  Autoantibodies Directed Against Domain I of Beta2-Glycoprotein I , 2011 .

[18]  M. Petri,et al.  Association of IgA Anti-ß2 Glycoprotein I with Clinical and Laboratory Manifestations of Systemic Lupus Erythematosus , 2011, The Journal of Rheumatology.

[19]  A. Tincani,et al.  Anti-β2-glycoprotein I IgG antibodies from 1-year-old healthy children born to mothers with systemic autoimmune diseases preferentially target domain 4/5: might it be the reason for their ‘innocent’ profile? , 2010, Annals of the rheumatic diseases.

[20]  P. D. de Groot,et al.  The association between circulating antibodies against domain I of beta2‐glycoprotein I and thrombosis: an international multicenter study , 2009, Journal of thrombosis and haemostasis : JTH.

[21]  T. Ortel,et al.  Update of the guidelines for lupus anticoagulant detection , 2009, Journal of thrombosis and haemostasis : JTH.

[22]  Y. Shoenfeld,et al.  Predictive, protective, orphan autoantibodies: the example of anti-phospholipid antibodies. , 2008, Autoimmunity reviews.

[23]  Juan de Dios Luna del Castillo,et al.  Comparison of the likelihood ratios of two binary diagnostic tests in paired designs , 2007, Statistics in medicine.

[24]  Y. Shoenfeld,et al.  International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS) , 2006, Journal of thrombosis and haemostasis : JTH.

[25]  G. M. Iverson,et al.  Use of Single Point Mutations in Domain I of β2-Glycoprotein I to Determine Fine Antigenic Specificity of Antiphospholipid Autoantibodies1 , 2002, The Journal of Immunology.

[26]  J. Reveille,et al.  Guidelines for immunologic laboratory testing in the rheumatic diseases: an introduction. , 2002, Arthritis and rheumatism.

[27]  G. M. Iverson,et al.  The Orientation of β2GPI on the Plate is Important for the Binding of Anti-β2GPI Autoantibodies by ELISA , 2002 .

[28]  G. M. Iverson,et al.  Anti-β2 glycoprotein I (β2GPI) autoantibodies recognize an epitope on the first domain of β2GPI , 1998 .

[29]  C. Chesterman,et al.  Anti-phospholipid antibodies are directed against a complex antigen that includes a lipid-binding inhibitor of coagulation: beta 2-glycoprotein I (apolipoprotein H). , 1990, Proceedings of the National Academy of Sciences of the United States of America.